Among the four patients with deleterious mutations, 3 had family history of breast cancer and 1 had bilateral breast cancer, and 2 had triple-negative breast cancer (estrogen and progesterone receptor negative, and HER2/neu negative). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.